Filing Flows › Mimedx Group (MDXG) › Q2 2025
Mimedx Group (MDXG) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 30, 2025
Mimedx Group (MDXG) reported revenue of $98.6M for the second quarter 2025 (Q2 2025), +13% from a year earlier and +12% from the quarter before. Operating margin was 12.5%, net earnings $9.6M (9.8% of revenue).
Mimedx Group, Q2 2025: revenue $98.6M (+13% year over year), operating margin 12.5%, net earnings $9.6M, operating cash flow $14.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $98.6M | +12% | +13% |
| Gross profit | $79.9M | +12% | +10% |
| Operating profit | $12.4M | +50% | -47% |
| Net earnings | $9.6M | +37% | -45% |
| Operating cash flow | $14.4M | +172% | -34% |
| Free cash flow | $14.2M | +189% | -34% |
What changed
Revenue was $98.6M in Q2 2025, up 13% year over year and up 12% from the previous quarter. Wound was the largest line at 65% of revenue. Wound added $6.9M year over year (up 12%), 61% of the total change.
Gross margin was 81.1%, down 1.9 points from a year earlier. Operating profit was $12.4M, a 12.5% margin (down 14.3 points year over year). Operating profit fell $11.1M even though revenue rose $11.4M versus a year earlier, so costs grew faster than sales. Operating expenses grew 38% against revenue growth of 13%. Net earnings were $9.6M, down 45% year over year. The effective tax rate was 26.1%.
Operating cash flow was $14.4M (down 34% year over year), 150% of net earnings. Non-cash charges added back $658K of depreciation and amortization and $4.8M of share-based compensation. Capital expenditures of $179K left free cash flow of $14.2M.
Questions
What was Mimedx Group's revenue in the second quarter 2025?
Mimedx Group (MDXG) reported revenue of $98.6M for the second quarter 2025 (Q2 2025), +13% from a year earlier and +12% from the quarter before.
Was Mimedx Group profitable in the second quarter 2025?
Operating profit was $12.4M (12.5% of revenue) and net earnings $9.6M.
Source: Mimedx Group 10-Q on SEC EDGAR.